English Typing Paragraph
▲
Polio was a devastating disease before the development of the polio vaccine. But now, this once-feared virus might help treat another deadly illness -
brain cancer. In a new study, some patients who had an aggressive type of brain cancer called glioblastoma and who received a genetically modified poliovirus
lived much longer than typical for these patients. The study found that about 21 percent of the brain cancer patients who received the poliovirus therapy
were alive three years later. In contrast, among a group of previously treated patients who had the same cancer but received standard therapies (such
as chemotherapy), just 4 percent were alive after three years. Still, the new study was small and wasn't designed to determine exactly how effective the
poliovirus therapy is, so future studies are needed to look at this question, the researchers said. What's more, it appears that most patients in the
study didn't respond to the new therapy at all. But the researchers said that the new results are promising and that they plan to conduct more studies
to see if they can increase the percentage of patients who benefit from the treatment. “Glioblastoma remains a lethal and devastating disease," senior
study author Dr. Darell Bigner, emeritus director of the Preston Robert Tisch Brain Tumor Center at the Duke Cancer Institute, said in a statement. "There
is a tremendous need for fundamentally different approaches" to treat the disease, Bigner said. "With the survival rates in this early phase of the poliovirus
brain cancer. In a new study, some patients who had an aggressive type of brain cancer called glioblastoma and who received a genetically modified poliovirus
lived much longer than typical for these patients. The study found that about 21 percent of the brain cancer patients who received the poliovirus therapy
were alive three years later. In contrast, among a group of previously treated patients who had the same cancer but received standard therapies (such
as chemotherapy), just 4 percent were alive after three years. Still, the new study was small and wasn't designed to determine exactly how effective the
poliovirus therapy is, so future studies are needed to look at this question, the researchers said. What's more, it appears that most patients in the
study didn't respond to the new therapy at all. But the researchers said that the new results are promising and that they plan to conduct more studies
to see if they can increase the percentage of patients who benefit from the treatment. “Glioblastoma remains a lethal and devastating disease," senior
study author Dr. Darell Bigner, emeritus director of the Preston Robert Tisch Brain Tumor Center at the Duke Cancer Institute, said in a statement. "There
is a tremendous need for fundamentally different approaches" to treat the disease, Bigner said. "With the survival rates in this early phase of the poliovirus
Note: Use Down arrow,Enter,page-down to move to Next Chunk, Use page up to Move to Previous Chunk ▼
Chunk Number: 1